Cerebral white matter lesions - associations with Aβ isoforms and amyloid PET

Scientific Reports

Volumn 6, Issue , 2016, Pages

  Van Westen, Danielle ^a,b   Lindqvist, Daniel ^a,c   Blennow, Kaj ^d   Minthon, Lennart ^b,e   Nägga, Katarina ^b,e   Stomrud, Erik ^b,e   Zetterberg, Henrik ^d,f   Hansson, Oskar ^b,e  

^a LUND UNIVERSITY   (Sweden)

^b LUND UNIVERSITY HOSPITAL   (Sweden)

^c Psychiatry Research Skåne   (Sweden)

^d UNIVERSITY OF GOTHENBURG   (Sweden)

^e LUND UNIVERSITY   (Sweden)

^f UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; ANILINE DERIVATIVE; BENZOTHIAZOLE DERIVATIVE; FLUTEMETAMOL; ISOPROTEIN;

AGED; ALZHEIMER DISEASE; CEREBROSPINAL FLUID; CLINICAL TRIAL; DIAGNOSTIC IMAGING; FEMALE; HUMAN; MALE; METABOLISM; MIDDLE AGED; POSITRON EMISSION TOMOGRAPHY; TEMPORAL LOBE; VERY ELDERLY; WHITE MATTER;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANILINE COMPOUNDS; BENZOTHIAZOLES; FEMALE; HUMANS; MALE; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY; PROTEIN ISOFORMS; TEMPORAL LOBE; WHITE MATTER;

EID: 84957812612     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep20709     Document Type: Article

References (61)

1. Pantoni, L. Cerebral small vessel disease: from pathogenesis and clinical characteristics to therapeutic challenges. Lancet Neurol. 9, 689-701 (2010).
2. Ylikoski, A. et al. White matter hyperintensities on MRI in the neurologically nondiseased elderly. Analysis of cohorts of consecutive subjects aged 55 to 85 years living at home. Stroke. 26, 1171-1177 (1995).
3. Breteler, M. M. et al. Cerebral white matter lesions, vascular risk factors, and cognitive function in a population-based study: the Rotterdam Study. Neurology 44, 1246-1252 (1994).
4. Longstreth, W. T. et al. Clinical correlates of white matter findings on cranial magnetic resonance imaging of 3301 elderly people. The Cardiovascular Health Study. Stroke. 27, 1274-1282 (1996).
5. Greenberg, S. M. et al. Microbleed Study Group. Cerebral microbleeds: a guide to detection and interpretation. Lancet Neurol. 8, 165-174 (2009).
6. Weller, R. O., Hawkes, C. A., Kalaria, R. N., Werring, D. J. & Carare, R. O. White matter changes in dementia: role of impaired drainage of interstitial fluid. Brain Pathol. 25, 63-78 (2015).
7. Grinberg, L. T. & Thal, D. R. Vascular pathology in the aged human brain. Acta Neuropathol. 119, 277-290 (2010).
8. Utter, S. et al. Cerebral small vessel disease-induced apolipoprotein E leakage is associated with Alzheimer disease and the accumulation of amyloid beta-protein in perivascular astrocytes. J Neuropathol Exp Neurol. 67, 842-856 (2008).
9. Czirr, E. et al. Independent generation of Abeta42 and Abeta38 peptide species by gamma-secretase. J Biol Chem. 283, 17049-17054 (2008).
10. Wang, R., Sweeney, D., Gandy, S. E. & Sisodia, S. S. The profile of soluble amyloid beta protein in cultured cell media. Detection and quantification of amyloid beta protein and variants by immunoprecipitation-mass spectrometry. J Biol Chem. 271, 31894-31902 (1996).
11. Suzuki, N. et al. An increased percentage of long amyloid beta protein secreted by familial amyloid beta protein precursor (beta APP717) mutants. Science. 264, 1336-1340 (1994).
12. Ozawa, K. 1. et al. Enhanced Abeta40 deposition was associated with increased Abeta42-43 in cerebral vasculature with Dutch-type hereditary cerebral hemorrhage with amyloidosis (HCHWA-D). Ann N Y Acad Sci. 977, 149-154 (2002).
13. Portelius, E. et al. Mass spectrometric characterization of brain amyloid beta isoform signatures in familial and sporadic Alzheimer's disease. Acta Neuropathol. 120, 185-193 (2010).
14. Casserly, I. & Topol, E. Convergence of atherosclerosis and Alzheimer's disease: inflammation, cholesterol, and misfolded proteins. Lancet. 363, 1139-1146 (2004).
15. Meng, X. F. et al. Midlife vascular risk factors and the risk of Alzheimer's disease: a systematic review and meta-analysis. J Alzheimers Dis. 42, 1295-1310 (2014).
16. Smith, E. E. & Greenberg, S. M. Beta-amyloid, blood vessels, and brain function. Stroke. 40, 2601-2606 (2009).
17. Zlokovic, B. V. Neurovascular pathways to neurodegeneration in Alzheimer's disease and other disorders. Nat Rev Neurosci. 12, 723-738 (2011).
18. Qiu, C. & Fratiglioni, L. A major role for cardiovascular burden in age-related cognitive decline. Nat Rev Cardiol. 12, 267-277 (2015).
19. Qiu, C. et al. Twenty-year changes in dementia occurrence suggest decreasing incidence in central Stockholm, Sweden. Neurology. 80, 1888-94 (2013).
20. Schrijvers, E. M. et al. Is dementia incidence declining? Trends in dementia incidence since 1990 in the Rotterdam Study. Neurology. 78, 1456-63 (2012).
21. Kester, M. I. et al. Associations between cerebral small-vessel disease and Alzheimer disease pathology as measured by cerebrospinal fluid biomarkers. JAMA Neurol. 71, 855-862 (2014).
22. McGowan, E. et al. Amyloid phenotype characterization of transgenic mice overexpressing both mutant amyloid precursor protein and mutant presenilin 1 transgenes. Neurobiol Dis. 6, 231-244 (1999).
23. De la Torre, J. C. Alzheimer disease as a vascular disorder: nosological evidence. Stroke. 33, 1152-1162 (2002).
24. Prelli, F., Castano, E., Glenner, G. G. & Frangione, B. Differences between vascular and plaque core amyloid in Alzheimer's disease. J Neurochem. 51, 648-651 (1988).
25. Reinert, J. et al. Aβ 38 in the brains of patients with sporadic and familial Alzheimer's disease and transgenic mouse models. J Alzheimers Dis. 39, 871-881 (2014).
26. Davis, J. 1. et al. Early-onset and robust cerebral microvascular accumulation of amyloid beta-protein in transgenic mice expressing low levels of a vasculotropic Dutch/Iowa mutant form of amyloid beta-protein precursor. J Biol Chem. 279, 20296-20306 (2004).
27. Hawkes, C. A. et al. Disruption of arterial perivascular drainage of amyloid-beta from the brains of mice expressing the human APOE epsilon4 allele. PLoS One. 7, e41636 (2012).
28. Hawkes, C. A., Carare, R. O. & Weller, R. O. Amyloid and tau in the brain in sporadic Alzheimer's disease: defining the chicken and the egg. Acta Neuropathol. 127, 617-618 (2014).
29. Gurol, M. E1. et al. Plasma beta-amyloid and white matter lesions in AD, MCI, and cerebral amyloid angiopathy. Neurology. 66, 23-29 (2006).
30. Verbeek, M. M. et al. Cerebrospinal fluid amyloid beta(40) is decreased in cerebral amyloid angiopathy. Ann Neurol. 66, 245-249 (2009).
31. Grinberg, L. T. & Thal, D. R. Vascular pathology in the aged human brain. Acta Neuropathol 119, 277-290 (2010).
32. Selnes, P. et al. Effects of cerebrovascular disease on amyloid precursor protein metabolites in cerebrospinal fluid. Cerebrospinal Fluid Res. 7, 10 (2010).
33. Garcia-Alloza, M. et al. Cerebrovascular lesions induce transient beta-amyloid deposition. Brain. 134, 3697-3707 (2011).
34. Debette, S. & Markus, H. S. The clinical importance of white matter hyperintensities on brain magnetic resonance imaging: systematic review and meta-analysis. BMJ. 341, c3666 (2010).
35. Zhou, Y., Yu, F. & Duong, T. Q. Alzheimer's Disease Neuroimaging Initiative. White matter lesion load is associated with resting state functional MRI activity and amyloid PET but not FDG in mild cognitive impairment and early Alzheimer's disease patients. J Magn Reson Imaging. 41, 102-109 (2015).
36. Palop, J. J. & Mucke, L. Amyloid-beta-induced neuronal dysfunction in Alzheimer's disease: from synapses toward neural networks. Nat Neurosci. 13, 812-818 (2010).
37. Hedden, T. et al. Cognitive profile of amyloid burden and white matter hyperintensities in cognitively normal older adults. J Neurosci. 32, 16233-16242 (2012).
38. Marchant, N. L. et al. The aging brain and cognition: contribution of vascular injury and aβ to mild cognitive dysfunction. JAMA Neurol. 70, 488-495 (2013).
39. Marchant, N. L. et al. Cerebrovascular disease, β -amyloid, and cognition in aging. Neurobiol Aging. 33, 1006.e25-36 (2012).
40. Park, J. H. et al. Effects of cerebrovascular disease and amyloid beta burden on cognition in subjects with subcortical vascular cognitive impairment. Neurobiol Aging. 35, 254-260 (2014).
41. Lockhart, A. et al. PIB is a non-specific imaging marker of amyloid-beta (Abeta) peptide-related cerebral amyloidosis. Brain 130, 2607-2615 (2007).
42. Ikonomovic, M. D. et al. Post-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer's disease. Brain 131, 1630-1645 (2008).
43. Ly, J. V. et al. 11C-PIB binding is increased in patients with cerebral amyloid angiopathy-related hemorrhage. Neurology 74, 487-493 (2010).
44. Baron, J. C. et al. Diagnostic utility of amyloid PET in cerebral amyloid angiopathy-related symptomatic intracerebral hemorrhage. J Cereb Blood Flow Metab. 34, 753-758 (2014).
45. Brickman, A. M. Contemplating Alzheimer's disease and the contribution of white matter hyperintensities. Curr Neurol Neurosci Rep. 13, 415 (2013).
46. Attems, J. & Jellinger, K. A. The overlap between vascular disease and Alzheimer's disease-lessons from pathology. BMC Med. 12, 206 (2014).
47. Kotagal, V. et al. Modifiable cardiovascular risk factors and axial motor impairments in Parkinson disease. Neurology. 82, 1514-20 (2014).
48. Toledo, J. B. et al. Contribution of cerebrovascular disease in autopsy confirmed neurodegenerative disease cases in the National Alzheimer's Coordinating Centre. Brain. 136, 2697-706 (2013).
49. Vemuri, P. et al. Vascular and amyloid pathologies are independent predictors of cognitive decline in normal elderly. Brain. 138, 761-71 (2015).
50. Manjer, J. et al. The Malmö diet and cancer study: Representativity, cancer incidence and mortality in participants and nonparticipants. Eur J Cancer Prev. 10, 489-499 (2001).
51. Folstein, M. F., Folstein, S. E. & McHugh, P. R. "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 12, 189-198 (1975).
52. Petersen, R. C. Mild cognitive impairment as a diagnostic entity. J Intern Med 256, 183-94 (2004).
53. McKhann, G. M. et al. The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 7, 263-269 (2011).
54. Gelb, D. J., Oliver, E. & Gilman, S. Diagnostic criteria for Parkinson disease. Arch Neurol. 56, 33-39 (1999).
55. Schmidt, P. et al. An automated tool for detection of FLAIR-hyperintense white-matter lesions in Multiple Sclerosis. Neuro Image. 59, 3774-3783 (2012).
56. Fazekas, F., Chawluk, J. B., Alavi, A., Hurtig, H. I. & Zimmerman, R. A. MR signal abnormalities at 1.5 T in Alzheimer's dementia and normal aging. AJR Am J Roentgenol. 149, 351-356 (1987).
57. Wahlund, L. O. et al. A new rating scale for age-related white matter changes applicable to MRI and CT. Stroke. 32, 1318-1322 (2001).
58. Wardlaw, J. M. et al. STandards for ReportIng Vascular changes on nEuroimaging (STRIVE v1). Neuroimaging standards for research into small vessel disease and its contribution to ageing and neurodegeneration. Lancet Neurol. 12, 822-838 (2013).
59. Blennow, K., Hampel, H., Weiner, M. & Zetterberg, H. Cerebrospinal fluid and plasma biomarkers in Alzheimer disease. Nat Rev Neurol. 6, 131-144 (2010).
60. Koole, M. et al. Whole-body biodistribution and radiation dosimetry of 18F-GE067: a radioligand for in vivo brain amyloid imaging. J Nucl Med. 50, 818-822 (2009).
61. Lundqvist, R. et al. Implementation and validation of an adaptive template registration method for 18F-flutemetamol imaging data. J Nucl Med. 54, 1472-1478 (2013).